TLR9 and neoplasm: Mice were treated with control oligonucleotide and control isotype antibody, the class A TLR9 agonist ODN1585 (5 nmol/mouse, i.p.)and control isotype antibody, control isotype antibody and anti–PD-1 antibody, or ODN1585 and anti–PD-1 antibody (ODN+anti–PD-1) every 3 days starting 1 week after tumor inoculation (Figure 1A).